Treatment combination improves survival in advanced HER2-positive breast cancer patie

[News]

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

More... (https://www.news-medical.net/news/20191211/Treatment-combination-improves-survival-in-advanced-HER2-positive-breast-cancer-patients.aspx)